I disagree. more dilution can be done and likely will. If

New Post Public Reply Private Reply Replies (0) Message Board
PowerPuncher MaxShockeR #472

I disagree. more dilution can be done and likely will. If A/S shares were cancelled (and let's put this in perspective-- the gagged TA will always allow Leonard to riase the A/S whenever he damn well pleases, and it forces shareholders to monitor the Secretary of Staet website so they don't get fleeced....But, I would, if I was a shareholder I'd rather monitor the state-site and have a heads up than have the CEO dump at will with a gagged TA and the A/S portion of the s.s. remaining as such with room to increase the O/S as you have NO WARNING).

In some ways, investing well imho, is like baseball - it is a game of inches. So, when CEO's imho "play dirty" you try to take back as much power, control, and info as you can. Especially if you are already stuck and invested with he/she.

Anyway, why more dilution? Because if Leonard is forced to make a go of the business here what would the dilutive downside risk be to shareholders? None really, price could go bidless but if he is improving the business you know say 2.5B is coming in but your back is against bidless. Shareholders would do well to accumulate there and pocket some of the shareholder equity you hope the CEO can bring to the stock.

However, Leonard will not likely ba ABLE to dilute there. So A) He hsa to get creative, find financing and pursue B) Off-balance-sheet options or C) Use the collatoral of equipment etc. Let's face it, credit has loosened and Tytan should be able to get some support in that regard as the Ag industry is BOOMING. And, if not, then his business plan sucks and others won't invest in him so shareholder downside again is minimized. Until he produces a workable plan that investors and finance experts can get behind.

Conversely the R/S creates false equity if the A/S isn't immediately reduced pre-split (to very near the O/S) and TA remains (gagged, unchanged, s.s. unposted daily) then expect the dilution to continue in secrecy, undetected by that avg shareholder. Why? Because a PIPE Funder will give Leonard 30% cash on the "lowest current" post-split pps and start selling right away. These PIPE Funding deals are so damn lucrative that they want to grab their money quickly so they can finance the next pipe deal. They don't give a rats nest about the company, pps integrity, or distributing in a manner that supports the long-term health of the stock. IT IS THE CEO'S responbility to get creative - find suitors and financing options so as NOT to allow this to happen to his shareholders. But Leonard has PROVEN he does not give a chit. He wants to claim working the hours, working hard for shareholders, putting in all the days and hours, making sure he answers your e-mail late at night, or on a weekend, but his actions do NOT match his words.

The PIPE deals btw remind me of Leonards F-U attitude (or at least how I read it). He sells them the paper at 60% or more discount (usually lowest 3-day pps for 3/6/12 mo -- whatever gives the pipe the lowest possible starting point, then they get the unrestricted shares at 40-80% off from that lowest 3 pps days over that lowest possible period). Some CEO's build good relationships and force selling parameters as part of their deal in which case the pipe may negotiate a bit less capital in exchange for the risks they assume - but in the end the pipe wants the shares converted to capital to put into the next very profitable deal, the faster the churn the better the return! The pps indicates this CEO just started dumping indiscriminantly. Go through filings, look at the increases, checkt he charts, you'll see what others have predicted about Leonards actions, NOT shareholder friendly one might say.

Anyway, that's just the start. Not here to fight folks! I am not the enemy. Take from my posts what you will. Excuse the insults upon Leonard, if you knew what I did about how he has been operating, what he has been told and the choices he has made, you might agree. For now, I'll just say that I would be very careful and more demanding of him as I don't believe he has earned any blind faith. It is my opinion that he has not, to this point in time, served shareholders well in any significantly measureable capacity that I can discern. I'll leave it at that.

Tytan Holdings Inc. (TYTN) Stock Research Links

TYTN Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 14

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 6

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading

Top 5 Most Recently Viewed Articles

You Call The Play Inc. (YCTP) Leads with Integrity in Betting

Updated Category News Views 154

Understanding You Call The Play Inc. (YCTP)'s Initiative In an important move for the sports betting landscape, You Call The Play Inc. (YCTP) has recently unveiled a national licensing plan and a groundbreaking measure called the Safe Bet Overlay™. This initiative is designed to foster trust and transparency within an industry that continues to grow rapidly across the...

Continue Reading
Cash for Houses Pro Earns Stellar Reputation with 5-Star Reviews

Updated Category News Views 167

Cash for Houses Pro Achieves 5-Star Reviews Cash for Houses Pro is celebrating their recent success in receiving numerous 5-star reviews on Google for their service known as 'Sell Your House Fast In Tampa FL For Cash'. This recognition reflects the team's dedication to providing homeowners with a seamless and stress-free home selling experience. About Cash for Houses Pro...

Continue Reading
Pfizer's Potential Transformation Following Starboard Investment

Updated Category News Views 77

Pfizer's Revised Price Target and Market Standing Recently, CFRA, a prominent financial research firm, elevated its price target for Pfizer Inc. (NYSE:PFE) from $30.00 to $31.00 per share. This adjustment comes while maintaining a 'Hold' rating on the stock, suggesting a careful observation of its market performance. The current price target reflects a valuation based on...

Continue Reading
Equinox Gold's Impressive Q2 Results Spark Stock Surge Today

Updated Category News Views 103

Equinox Gold Delivers Strong Quarterly Performance Equinox Gold Corp. EQX has seen its shares rise significantly following the release of its second-quarter financial results, which exceeded market expectations. Investors reacted favorably, driving the stock up on Thursday. Financial Highlights from the Quarter In the latest quarterly report, Equinox Gold announced...

Continue Reading
Investor Insights on Alexandria Real Estate Equities' Legal Challenges

Updated Category News Views 219

Understanding the Alexandria Real Estate Equities, Inc. Lawsuit Investors have an important opportunity arising from a lawsuit against Alexandria Real Estate Equities, Inc. (NYSE: ARE). A national shareholder rights litigation firm has initiated a class action alleging the Company has violated various securities laws. This situation has caught the attention of many...

Continue Reading